Eric Sagonowsky | FiercePharma
Among the many meds that’ll lose patent
protection in the U.S. this year are 10 drugs that each contribute in a big way
for top drugmakers. Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb and Gilead
are each set to hit the patent cliff this year with some of their respective
big sellers.
Together, they brought in more than $10 billion
last year in the U.S. and cover a range of indications: multiple sclerosis,
HIV, erectile dysfunction and cancer, among others. They’ll be hot targets as
generic rivals rush to steal share with cheaper options.
Just when a drug will lose market exclusivity
isn’t always clear, with add-on patents and legal settlements occasionally
clouding the picture. We've focused not only on drugs that will lose their
patent shields in 2017, but those that, because of patent litigation or
settlements, will find themselves vulnerable to generic or biosimilar
competition.